



## Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026

April 21, 2026

PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- [Krystal Biotech, Inc.](#) (the "Company") (NASDAQ: KRYS) announced today that it will report its first quarter 2026 financial results on Monday, May 4, 2026, prior to the open of U.S. markets.

The Company's management will also host a conference call and webcast at 8:30 am ET on Monday, May 4, 2026, to discuss the financial results and provide a business update.

Investors and the general public can access the live webcast at: <https://www.webcaster5.com/Webcast/Page/3018/53916>.

For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company's website at [www.krystalbio.com](http://www.krystalbio.com).


### **About Krystal Biotech, Inc.**

Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK<sup>®</sup>, the Company's first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit <http://www.krystalbio.com>, and follow @KrystalBiotech on [LinkedIn](#) and [X](#) (formerly Twitter).

### **CONTACT**

#### **Investors and Media:**

Stéphane Paquette, PhD  
Krystal Biotech  
[spaquette@krystalbio.com](mailto:spaquette@krystalbio.com)



Source: Krystal Biotech, Inc.